Testing and therapeutic stocks will be important in future of COVID-19 variants: Dawson James Securities' Kolbert
Jason Kolbert, director of research at Dawson James Securities, discusses how the Omicron variant is impacting confidence in the market as health studies are showing a high infection rate, but low mortality. Kolbert says that cases will keep rising as coronavirus variations are not going away anytime soon and society needs to learn to live with them.